Botanix Pharmaceuticals Limited
BXPHF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $5,757 | $2,069 | $3,772 | $2,755 |
| % Growth | 178.2% | -45.1% | 36.9% | – |
| Cost of Goods Sold | $3,439 | $3,652 | $3,961 | $10,293 |
| Gross Profit | $2,319 | -$1,583 | -$3,046 | -$7,538 |
| % Margin | 40.3% | -76.5% | -80.7% | -273.6% |
| R&D Expenses | $144 | $1,813 | $5,727 | $10,293 |
| G&A Expenses | $33,030 | $6,648 | $3,038 | $3,556 |
| SG&A Expenses | $71,489 | $6,979 | $4,022 | $3,556 |
| Sales & Mktg Exp. | $38,459 | $331 | $984 | $0 |
| Other Operating Expenses | $17,028 | $5,357 | $0 | $1,061 |
| Operating Expenses | $88,662 | $14,150 | $9,750 | $14,910 |
| Operating Income | -$86,343 | -$15,460 | -$13,612 | -$22,447 |
| % Margin | -1,499.7% | -747% | -360.8% | -814.8% |
| Other Income/Exp. Net | -$53 | $1,863 | $4,458 | $9,277 |
| Pre-Tax Income | -$86,396 | -$13,870 | -$9,154 | -$13,171 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$86,396 | -$13,870 | -$9,154 | -$13,171 |
| % Margin | -1,500.6% | -670.2% | -242.7% | -478.1% |
| EPS | -0.047 | -0.009 | -0.008 | -0.014 |
| % Growth | -408.7% | -16.5% | 41.5% | – |
| EPS Diluted | -0.047 | -0.009 | -0.008 | -0.014 |
| Weighted Avg Shares Out | 1,844,974 | 1,501,701 | 1,153,952 | 973,142 |
| Weighted Avg Shares Out Dil | 1,844,974 | 1,501,564 | 1,153,952 | 973,142 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,877 | $76 | $66 | $37 |
| Interest Expense | $1,971 | $11 | $82 | $37 |
| Depreciation & Amortization | $2,264 | $73 | $110 | $143 |
| EBITDA | -$82,162 | -$13,786 | -$8,962 | -$12,990 |
| % Margin | -1,427.1% | -666.2% | -237.6% | -471.5% |